Loading
NASDAQHealthcareMedical - Devices
Latest quote
$1.23
+$0.03 · +2.50%
Rapid Micro Biosystems, Inc. operates as a life sciences technology firm, supplying advanced solutions for identifying microbial impurities in the production processes of pharmaceuticals, medical devices, and personal care goods across North America, Europe, and Asia. Central to their offerings is the Growth Direct platform, a comprehensive system comprising the Growth Direct instrument, specialized disposable components, software for seamless integration with laboratory information management systems (LIMS), and extensive customer validation and support services. This innovative platform is designed to automate and modernize traditional, labor-intensive microbial quality control (MQC) testing workflows, which are critical for diverse therapeutic modalities such as biologics, vaccines, cutting-edge cell and gene therapies, and sterile injectable medications. Beyond their core product, the company also delivers essential services, including system installation, verification, expert technical training, and continuous support. Their technologies are widely applied in vital areas like environmental monitoring, water quality testing, bioburden assessment, and final sterility release evaluations. Established in 2006, the company initially traded as Genomic Profiling Systems, Inc., before rebranding to Rapid Micro Biosystems, Inc. in January 2007, and maintains its headquarters in Lowell, Massachusetts.
Previous close
$1.23
+$0.03 · +2.50%
Regular session · ET · Market data may be delayed.
Rapid Micro Biosystems, Inc. operates as a life sciences technology firm, supplying advanced solutions for identifying microbial impurities in the production processes of pharmaceuticals, medical devices, and personal care goods across North America, Europe, and Asia. Central to their offerings is the Growth Direct platform, a comprehensive system comprising the Growth Direct instrument, specialized disposable components, software for seamless integration with laboratory information management systems (LIMS), and extensive customer validation and support services. This innovative platform is designed to automate and modernize traditional, labor-intensive microbial quality control (MQC) testing workflows, which are critical for diverse therapeutic modalities such as biologics, vaccines, cutting-edge cell and gene therapies, and sterile injectable medications. Beyond their core product, the company also delivers essential services, including system installation, verification, expert technical training, and continuous support. Their technologies are widely applied in vital areas like environmental monitoring, water quality testing, bioburden assessment, and final sterility release evaluations. Established in 2006, the company initially traded as Genomic Profiling Systems, Inc., before rebranding to Rapid Micro Biosystems, Inc. in January 2007, and maintains its headquarters in Lowell, Massachusetts.
Day range
Current $1.23
52-week range
Current $1.23
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
60
Fair Value
Sentiment
65
Bullish
Risk
76
High Risk
Momentum
37
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Rapid Micro Biosystems, Inc. operates as a life sciences technology firm, supplying advanced solutions for identifying microbial impurities in the production processes of pharmaceuticals, medical devices, and personal care goods across North America, Europe, and Asia. Central to their offerings is the Growth Direct platform, a comprehensive system comprising the Growth Direct instrument, specialized disposable components, software for seamless integration with laboratory information management systems (LIMS), and extensive customer validation and support services. This innovative platform is designed to automate and modernize traditional, labor-intensive microbial quality control (MQC) testing workflows, which are critical for diverse therapeutic modalities such as biologics, vaccines, cutting-edge cell and gene therapies, and sterile injectable medications. Beyond their core product, the company also delivers essential services, including system installation, verification, expert technical training, and continuous support. Their technologies are widely applied in vital areas like environmental monitoring, water quality testing, bioburden assessment, and final sterility release evaluations. Established in 2006, the company initially traded as Genomic Profiling Systems, Inc., before rebranding to Rapid Micro Biosystems, Inc. in January 2007, and maintains its headquarters in Lowell, Massachusetts.
Day range
Current $1.23
52-week range
Current $1.23
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 33.59M USD | 28.05M USD | 22.52M USD | 17.13M USD | 23.23M USD |
| Cost of goods sold | 25.98M USD | 28.16M USD | 28M USD | 25.67M USD | 30.97M USD |
| Gross profit | 7.61M USD | −109K USD | −5.49M USD | −8.54M USD | −7.74M USD |
| Research and development | 13.6M USD | 14.6M USD | 12.82M USD | 12.87M USD | 9.78M USD |
| Selling, general, and administrative | 34.84M USD | 35.21M USD | 38.26M USD | 41.81M USD | 29.71M USD |
| Operating expenses | 55M USD | 49.81M USD | 51.08M USD | 54.68M USD | 39.49M USD |
| Interest income | 1.51M USD | 3.16M USD | 4.21M USD | 1.78M USD | — |
| Interest expense | 1.09M USD | — | — | — | 2.65M USD |
| Depreciation and amortization | 3.25M USD | 3.36M USD | 3.11M USD | 2.84M USD | 1.53M USD |
| Operating income | −47.39M USD | −49.92M USD | −56.56M USD | −63.22M USD | −47.23M USD |
| Net income | −47.12M USD | −46.89M USD | −52.47M USD | −60.81M USD | −73.52M USD |
Company facts updated Sep 13, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI1.6M0.00%2.3T USD0.03%$376.31+0.82%
Vanguard Extended Market ETFVXF431.88K0.00%93.7B USD0.05%$237.76+0.68%
iShares Micro-Cap ETFIWC134.78K0.01%1.44B USD0.60%$190.84+0.39%
Dimensional - US Small Cap ETFDFAS36.85K0.00%15.49B USD0.26%$80.52+0.64%
U.S. Micro Cap Portfolio ETFDFMC17.24K0.00%7.73B USD0.43%$59.13+0.67%
Avantis U.S. Small Cap Equity ETFAVSC13.97K—3.09B USD0.25%$71.48+0.53%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCDimensional - US Small Cap ETFDFASU.S. Micro Cap Portfolio ETFDFMCAvantis U.S. Small Cap Equity ETFAVSCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
